20cm速递|创业板医药ETF国泰（159377）回调超1.6%，行业或进入商业化和政策加速期，回调或可布局

Group 1 - The surgical robot industry is entering a period of commercialization and policy acceleration, with a slight year-on-year increase in sales volume from January to November 2025 [1] - Sales of orthopedic surgical robots have increased in both volume and revenue, with revenue growth outpacing volume growth [1] - The National Healthcare Security Administration has established a pricing management framework for robotic surgeries, aiming to address industry pain points such as inconsistent pricing and lack of standards, which is expected to enhance transparency and comparability in pricing [1] Group 2 - The medical device sector is anticipated to gradually recover in profitability as centralized procurement policies are implemented, correcting previous inefficiencies and leading to valuation recovery [1] - The replacement of old medical equipment and the steady progress of large equipment configuration certificates are expected to catalyze related sectors such as brain-computer interfaces, AI healthcare, and surgical robots [1] - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which focuses on innovative pharmaceutical sectors and aims to reflect the overall performance of leading companies with high R&D investment and innovation capabilities [1]